Castle Biosciences
Update in progressCSTL (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
Castle Biosciences is a molecular diagnostics company delivering test solutions for dermatologic cancers, Barrett’s esophagus, atopic dermatitis, and uveal melanoma. Its products include DecisionDx-Melanoma (gene expression profile for melanoma risk), TissueCypher (spatialomics for esophageal cancer risk), AdvanceAD-Tx (non-invasive AD treatment guidance), DecisionDx-SCC, MyPath Melanoma, and DecisionDx-UM. Markets: dermatology and GI. Founded 2007; based in Friendswood, Texas.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!